Two years of growth hormone replacement therapy in a group of patients with Sheehan's syndrome

Pituitary

Volumn 9, Issue 2, 2006, Pages 127-135

  Soares, Débora Vieira ^a   Spina, Luciana Diniz Carneiro ^a   de Lima Oliveira Brasil, Rosane Resende ^a   Lobo, Priscila Marise ^a   Salles, Elizabeth ^a   Coeli, Claúdia Medina ^a   Conceição, Flávia Lúcia ^a   Vaisman, Mario ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

Atherosclerosis; Carotid artery; Growth hormone deficiency; Insulin sensitivity; Lipids; Sheehan's syndrome

Indexed keywords

APOLIPOPROTEIN A; APOLIPOPROTEIN B; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; ESTROGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HUMAN GROWTH HORMONE; INSULIN; LEVOTHYROXINE; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PREDNISONE; SOMATOMEDIN C; TRIACYLGLYCEROL;

ADULT; ARTERIOGRAPHY; ARTERY INTIMA; ARTERY MEDIA; ARTICLE; BODY FAT DISTRIBUTION; BODY MASS; CAROTID ARTERY; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DRUG DOSE REGIMEN; FEMALE; GLUCOSE INTOLERANCE; GLUCOSE METABOLISM; HORMONE DEFICIENCY; HORMONE SUBSTITUTION; HUMAN; HYPOPITUITARISM; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID ANALYSIS; MAINTENANCE DRUG DOSE; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

ADULT; BODY COMPOSITION; CAROTID ARTERIES; CHOLESTEROL, HDL; DOSE-RESPONSE RELATIONSHIP, DRUG; GLUCOSE; GROWTH HORMONE; HORMONE REPLACEMENT THERAPY; HUMANS; HYPOPITUITARISM; INSULIN; INTRA-ABDOMINAL FAT; LONGITUDINAL STUDIES; MIDDLE AGED; PROSPECTIVE STUDIES; TRIGLYCERIDES;

EID: 33749134819     PISSN: 1386341X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11102-006-9990-9     Document Type: Article

References (67)

1. Rosén T, Bengtsson B-Å (1990) Premature mortality due to cardiovascular disease in hypopituitarism. Lancet 336:285-288
2. Bülow B, Hagmar L, Mikoczy Z, Nordstrom CH, Erfurth EM (1997) Increased cerebrovascular mortality in patients with hypopituitarism. Clin Endocrinol (Oxf) 46:75-81
3. Bates AS, Bullivant B, Clayton RN, Sheppard MC, Stwert PM (1997) Increased mortality in hypopituitarism is not due to an increase in vascular mortality. J Endocrinol 152(suppl):OC9
4. Bates AS, Van't Hoff W, Jones PJ, Clayton RN (1996) The effect of hypopytuitarism of life expectancy. J Clin Endocrinol Metab 81:1169-1172
5. Tomlinson JW, Holden N, Hills RK et al (2001) Association between premature mortality and hypopituitarism. Lancet 357:425-431
6. Rosén T, Edén S, Larson G, Wilhelmsen L, Bengtsson B-Å 1993 Cardiovascular risk factors in adult patients with growth hormone deficiency. Acta endocrinol 29 195-200
7. Markussis V, Beshyam SA, Fisher C, Sharp P, Nicolaides NA, Johnston DG (1992) Detection of premature atherosclerosis by high-resolution ultrasonography in symptom-free hypopituitary adults. Lancet 340:1188-1192
8. Binnerts A, Deurenberg P, Swart GR, Wilson JHP, Lamberts SWJ (1992) Body composition in growth hormone-deficient adults. Am J Clin Nutr 55:918-923
9. Johanson J-O, Fowelin J, Landin K, Larger I, Bengtsson B-Å (1995) Growth hormone deficient adults are insulin-resistant. Metabolism 44:1126-1129
10. Johanson J.-O. Landin K. Tengborn L. Rosén T. Bengtsson B.-Å. (1994) High fibrinogen and plasminogen activator inhibitor activity in growth hormone-deficient adults. Arterioscler Thromb 14:434-437
11. Cuneo RC, Salomon F, Wiles CM, Hesp R, Sönksen PH (1991) Growth hormone treatment in growth hormone deficient adults. II Effects on exercise performance. J Appl Physiol 70:695-700
12. Sheehan HL (1973) Postpartum necrosis of anterior pituitary. J Pathol Bact 45:189-214
13. Beshyah SA (1999) Is cardiovascular mortality increased in hypopituitary adults? In: Monson JP (ed) Challenges in growth hormone therapy. Philadelphia, Blackwell Science, pp 93-105
14. Carrol PV, Christ ER, Bengtsson B-Å et al (1998) Growth hormone deficiency in adulthood and the effects of growth hormone replacement: A review. Growth Hormone Research Society Scientific Committee. J Clin Endocrinol Metab 83:382-385
15. Salomon F, Cuneo RC, Hesp R, Sönksen PH (1989) The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency. N Engl J Med 321:1797-1803
16. Jørgensen JOL, Pedersen SA, Thuesen L et al (1989) Beneficial effect of growth hormone treatment in GH-deficient adults. Lancet 1:1221-1225
17. Davidson MB (1987) Effect of growth hormone on carbohydrate and lipid metabolism. Endocr Rev 8:115-131
18. Bratusch-Marrain PR, Smith D, DeFronzo RA (1982) The effect of growth hormone on glucose metabolism and insulin secretion in man. J Clin Endocrinol Metab 55:973-982
19. Kelestimur F, Jonsson P, Molvalidar S et al (2005) Sheehan's syndrome: baseline characteristics and effect of 2 years of growth hormone replacement therapy in 91 patients in KIMS-Pfizer International Metabolic Database. Eur J Endocrinol 152:581-587
20. Tanriverdi F, Unluhizarci K, Kula M et al (2005) Effects of 18-month of growth hormone (GH) replacement therapy in patients with Sheehan's syndrome. Growth Horm IGF Res 15:231-237
21. Mathews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis Model Assessment: Insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412-419
22. Matsuda M, Defronzo RA (1999) Insulin sensitivity indices obtained from oral glucose tolerance test: Comparison with the euglycemic clamp. Diabetes Care 22:1462-1470
23. The Expert Committee on the diagnosis and classification of diabetes mellitus (1997) Report of the Expert Committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 20:1183-1197
24. Pignoli P, Tremoli H, Poli A, Oreste P, Paoletti R (1986) Intimal plus medial thickness of the arterial wall: A direct measurement with ultrasound imaging. Circulation 74:1399-1406
25. Soares DV, Spina LDC, Brasil RRLO et al (2005) Carotid artery intima-media thickness and lipid profile in adults with growth hormone deficiency after long-term growth hormone replacement. Metabolism 54:321-329
26. Spina LDC, Soares DV, Brasil RRLO et al (2005) Glucose metabolism and visceral fat in GH deficient adults: Two years of GH-replacement. Pituitary 7:1-7
27. Angerer P, Störk S, Kothny W, Schimitt P, von Schacky C (2001) Effects of oral postmenopausal hormone replacement on progression of atherosclerosis. Arterioscl Thormb Vasc Biol 21:262-268
28. Blankenhorn DH, Selzer RH, Crawford DW et al (1993) Beneficial effects of cholestipol-niacin therapy on the common carotid artery. Circulation 88:20-28
29. Hodis HN, Mack WJ, LaBree L et al (1996) Reduction in carotid arterial wall thickness using lovastatin and dietary therapy: A randomized controlled clinical trial. Ann Intern Med 124:548-556
30. Pfeifer M, Verhovec R, Žižek B, Preželj J, Poredoš P, Clayton RN (1999) Growth (GH) hormone treatment reverses early atherosclerotic changes in GH-deficient adults. J Clin Endocrinol Metab 84:453-457
31. Murata M, Kaji H, Mizuno I et al (2003) A study of carotid intima-media thickness in GH-deficient Japanese adults during onset among adults and children. Eur J Endocrinol 148:333-338
32. Lanes R, Gunczler P, Lopez E, Esaa S, Villaroel O, Revel-Chion R (2001) Cardiac mass and function, carotid artery intima-media thickness and lipoprotein levels in growth hormone-deficient adolescents. J Clin Endocrinol Metab 86:1061-1065
33. Bülow B, Hagmar L, Eskilsson J, Erfurth EM (2000) Hypopituitary females have a high incidence of cardiovascular morbidity and increased prevalence of cardiovascular risk factors. J Clin Endocrinol Metab 85:574-584
34. Elhadd TA, Abdu TA, Oxtoby J et al (2001) Biochemical and biophysical markers of endothelial dysfunction in adults with hypopituitarism and severe GH deficiency. J Clin Endocrinol Metab 86:4223-4232
35. Borson-Chazot F, Serusclat A, Kalfallah Y et al (1999) Decrease in carotid intima-media thickness after one year growth hormone (GH) treatment in adults with GH deficiency. J Clin Endocrinol Metab 84:1329-1333
36. Gibney J, Wallace JD, Spinks T et al (1999) The effects of 10 years of recombinant human growth hormone (GH) in adults GH-deficient patients. J Clin Endocrinol Metab 84:2596-2602
37. Svensson J, Fowelin J, Landin K, Bengtsson B-Å, Johansson J-O (2002) Effects of seven years of GH-replacement therapy on insulin sensitivity in GH-deficient adults. J Clin Endocrinol Metab 87:2121-2127
38. Johansson J-O, Landin K, Johannsson G, Tengborn L, Bengtsson B-Å (1996) Long-term treatment with growth hormone decreases plasminogen activator inhibitor-1 and tissue plasminogen activator in growth hormone-deficient adults. Thromb and Haemost 76:422-428
39. O'Neal DN, Hew FL, Best JD, Aford F (1999) The effect of 24 months recombinant human growth hormone (rh-GH) on LDL cholesterol, triglyceride-rich lipoproteins and apo[a] in hypopituitary adults previously treated with conventional replacement therapy. Growth Horm IGF Res 9:165-173
40. Koranyi J, Svensson J, Götherstr̈m G, Sunnerhagen KS, Bengtsson B-Å, Johannsson G (1999) Baseline Characteristics and the effects of five years of GH replacement therapy in adults with GH deficiency of childhood or adulthood onset: A comparative, prospective study. J Clin Endocrinol Metab 86:4693-4699
41. Al-Shoumer KAS, Gray R, Anyaoku V et al (1998) Effects of four years' treatment with biosynthetic human growth hormone (GH) on glucose homeostasis, insulin secretion and lipid metabolism in GH-deficient adults. Clin Endocrinol 48:795-802
42. Götherström G, Svensson J, Koranyi J et al (2001) A prospective study of 5 years of GH replacement therapy in GH-deficient adults: Sustained effects on body composition, bone mass and metabolic indices. J Clin Endocrinol Metab 86:4657-4665
43. Nolte W, Rädisch C, Armstrong VW, Hüfner M, von zur Mühlen A (1997) The effect of recombinant human GH replacement therapy on lipoprotein(a) and other lipid parameters in adults with acquired GH deficiency: Results of a double-blind and placebo-controlled trial. Eur J Endocrinol 137:459-466
44. Murray RD, Wieringa GE, Lissett CA, Darzy KH, Smethurst LE, Shalet MS (2002) Low-dose GH replacement improves the adverse lipid profile associated with the adult GH deficiency syndrome. Clin Endocrinol 56:525-532
45. Garry P, Collins P, Devlin JD (1996) An open 36-month study of lipid changes with growth hormone in adults: Lipid changes following replacement of growth hormone in adults acquired growth hormone deficiency. Eur J Endocrinol 134:61-66
46. Chirsoulidou A, Beshyah SA, Rutherford O et al (2000) Effects of 7 years of growth hormone replacement therapy in hypopituitary adults. J Clin Endocrinol Metab 85:3762-3769
47. Webster JM, Stewart M, Al-Maskari M et al (1997) The effect of growth hormone replacement therapy for up to 12 months on lipoprotein composition and lipoprotein(a) in growth hormone deficient adults. Atherosclerosis 133:115-121
48. Beshyah SA, Henderson A, Niththyananthan R et al (1995) The effects of short and long term growth hormone replacement therapy in hypopituitary adults on lipid metabolism and carbohydrate tolerance. J Clin Endocrinol Metab 80:356-363
49. Modigliani E, Kerchouni R, Uzzan B, Valensi P, Chanson P, Caron J (1994) Modification of blood lipids and lipoproteins after human growth hormone treatment in adults with growth hormone deficiency: A preliminary report. Endocrinol and Metab 1(Suppl A):31-35
50. Weaver JU, Monson JP, Noonan K et al (1995) The effect of low dose recombinant human growth hormone replacement on regional fat distribution, insulin sensitivity, and cardiovascular risk factors in hypopituitary adults. J Clin Endocrinol Metab 80:153-159
51. Johannsson G, Oscarsson J, Rosén T et al (1995) Effects of 1 year of growth hormone therapy on serum lipoprotein levels in growth hormone-deficient adults. Influence of gender and apo(a) and apoE phenotypes. Arterioscler Thromb Vasc Biol 15:2142-2150
52. Yusuf S, Hawken S, Öunpuu S et al (2004) Effect of potentially modifiable risk factors associated with myocardial infartation in 52 countries (the INTERHEART study): Case control study. Lancet 364:937-952
53. Walldius G, Jungner I, Aastveit AH et al (2004) The apoB/apoA-I ration is better than the cholesterol rations to estimate the balance between plasma proatherogenic and antiatherogenic lipoproteins and to predict coronary risk. Clin Chem Lab Med 42:1355-1363
54. Mersebach H, Rasmussen AK, Feldt-Rasmussen U (2004) Body composition and effects of growth hormone. In: Abs R Rasmussen F (eds). Growth hormone deficiency in adults: 10 years of KIMS. Oxford, UK. Oxford Phama Genesis TM Ltd; pp 117-126
55. Rosenfalck AM, Maghsoudi S, Fisker S et al (2000) The effect of 30 months of low dose replacement therapy with recombinant human growth hormone (rhGH) on insulin and c-peptide kinetics, insulin secretion, insulin sensitivity, glucose effectiveness, and body composition in GH-deficient adults. J Clin Endocrinol Metab 85:4173-4181
56. Spina LDC, Soares DV, Brasil RRLO et al (2004) Glucose metabolism and visceral fat in GH defiancient adults: 1 year of GH replacement. Growth Horm IGF Res 14:45-51
57. Hew FL, Koschmann M, Chirstopher M et al (1996) Insulin resistance in growth hormone-deficient adults: Defects in glucose utilization and glycogen synthase activity. J Clin Endocrinol Metab 81:555-564
58. Seminara S, Merello G, Masi S et al (1998) Effect of long-term growth hormone treatment on carbohydrate metabolism in children with growth hormone deficiency. Clinical Endocrinol (Oxf) 49:125-130
59. Fernholm R, Bramnert M, Hagg E et al (2000) Growth hormone replacement therapy improves body composition and increases bone metabolism in elderly patients with pituitary disease. J Clin Endocrinol Metab 85:4104-4112
60. Cutfield WS, Wilton P, Bennmark H et al (2000) Incidence of diabetes mellitus and impaired glucose tolerance in children and adolescents receiving growth hormone treatment. Lancet 355:610-613
61. Al Shoumer KAS, Page B, Thomas E, Murphy M, Beshyah SA, Johnston DG (1996) Effects of four years' treatment with biosynthetic human growth hormone (GH) on body composition in GH-deficient hypopituitary adults. Eur J Endocrinol 135:559-567
62. Fowelin J, Attvall S, Lager I, Bengtsson B-A (1993) Effects of treatment with recombinant human growth hormone on insulin sensitivity and glucose metabolism in adults with growth hormone deficiency. Metabolism 42:1443-1447
63. Jorgensen JO, Thuesen L, Muller J, Ovesen P, Skakkebaek NE, Christiansen JS (1994) Three years of growth hormone treatment in growth hormone-deficient adults: Near normalization of body composition and physical performance. Eur J Endocrinol 130:224-228
64. Monson JP, Bengtsson BA, Abs R, Feldt-Rasmussen U, Wuster C (2000) Can growth hormone therapy cause diabetes? KIMS Strategic Committee. Lancet 355:1728-1729
65. Yuen K, Ong K, Husbands S et al (2002) The effects of short-term administration of two low doses versus the standard GH replacement dose on insulin sensitivity and fasting glucose levels in young healthy adults. J Clin Endocrinol Metab 87:1989-1995
66. Micic D, Cvijovic G, Doknic M, Kendereski A, Popovic V (2002) Effect of 12 months of recombinant human growth hormone replacement therapy on insulin sensitivity in GH-deficient adults as determined by different methods. J Post Grad Med 48:260-265
67. Soares DV, Conceição FL, Brasil RRLO et al (2004) Insulin-like growth factor I levels during growth hormone (GH) replacement in GH-deficient adults: A gender difference. Growth Horm IGF Res 14:436-441